Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIR101 versus post-transplant cyclophosphamide after haploidentical HSCT in hematologic malignancies
2016-004672-21Phase 3Completed
- Sponsor
- Kiadis Pharma
- Start
- Feb 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ATIR101 in hematopoietic malignancies, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 1 more (2 arms), sponsored by Kiadis Pharma. Primary endpoint: GVHD-free, relapse-free survival. Started Feb 2017; status: completed.
02
Drugs
ATIR101
03
Conditions
hematopoietic malignanciesacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2016-004672-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004672-21.